Welcome to IVF
Welcome to IVF
Welcome to IVF
Bladder cancer
We have introduced a new FISH-based test at Jaslok Hospital using the Vysis UroVysion Kit. This is the first FDA-cleared genomic DNA-probe test for monitoring recurrence of bladder cancer. The test is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus (containing the p16 tumor suppressor gene), which is one of the most common alterations in urothelial carcinoma.  Results from the UroVysion Kit are intended for use in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria, and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.

  • UroVysion detects chromosomal abnormalities associated with the development and progression of bladder cancer.
  • UroVysion in conjunction with cystoscopy delivers the best balance of sensitivity (97%) and specificity (95%). 
  • It allows for more accurate patient monitoring, by detecting bladder cancer recurrence up to 6 months sooner than current diagnostic methods. 
  • It is more sensitive than cytology and reduces the false negatives. 
  • The UroVysion kit detects all stages and grades of bladder cancer.  It is highly sensitive for more dangerous higher grade and stage tumors. 
  • The test is not affected by BCG immunotherapy.
Early detection of high grade disease is critical to increased survival.